SEP 29, 2020 9:28 AM PDT

Gut microbiome influences oral therapy for prostate cancer treatment

Research from a team of scientists at Lawson Health Research Institute and Western University suggests that bacteria in the gut affect how prostate cancer patients receive an oral medication called abiraterone acetate. While the influence of the gut microbiome is nothing new, the researchers say their findings add to the plethora of evidence supporting the important role that gut bacteria play in the body.

"Research is beginning to uncover the ways in which the human microbiome influences cancer development, progression, and treatment," explains Brendan Daisley. "Our study highlights a key interaction between a cancer drug and the gut microbiome that results in beneficial organisms with anti-cancer properties."

Their findings, published in Nature Communications, show how gut bacteria metabolize abiraterone acetate in order to reduce harmful organisms while promoting those that fight cancer. This finding provides greater insight on an alternative path to prostate cancer treatment, which is traditionally treated with therapies that reduce tumor-causing hormones called androgens.

"Unfortunately, traditional androgen deprivation therapies are not always effective," explains Dr. Joseph Chin, Lawson Associate Scientist. "In those cases, alternative therapies are explored."

While abiraterone acetate has already been shown to be an effective treatment, understanding the full impact that the drug has on the body – and that the body has on the drug – is crucial to optimizing effectiveness.

"When drugs are taken orally, they make their way through the intestinal tract where they come into contact with billions of microorganisms," says lead researcher Dr. Jeremy Burton. "While it's long been a mystery why abiraterone acetate is so effective, our team wondered if the gut microbiome plays a role."

Photo: Pixabay

In conducting their study, the team analyzed stool samples from 68 prostate cancer patients undergoing abiraterone acetate treatment and traditional androgen deprivation therapies. From this analysis, they found that patients' gut microbiomes changed significantly following the ingestion of abiraterone acetate and that androgen levels also decreased. As reports Eureka Alert:

“Bacteria in the gut metabolized the drug leading to a significant increase in a bacterium called Akkermansia muciniphila. Referred to as a 'next-generation probiotic,' this bacterium's relevance has recently been explored in several large cancer studies. It's been shown to facilitate a better response to cancer immunotherapy drugs and it can elicit a wide range of other positive health benefits as well. The increase in Akkermansia muciniphila also led to an increased production of vitamin K2 which is known for anti-cancer properties that can inhibit tumor growth.”

From these findings, the team intends to continue their investigations in order to determine whether fecal transplants could improve responses to oral and immunotherapy cancer treatments. "While more research is needed, we may one day be able to analyze a patient's microbiome to determine the best course of treatment or even influence the microbiome to improve outcomes," says Dr. Burton. "This could lead to a new frontier in personalized medicine."

Sources: Nature Communications, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
DEC 02, 2020
Immunology
A Shingles Vaccine for Cancer Patients
DEC 02, 2020
A Shingles Vaccine for Cancer Patients
Receiving a vaccine (usually in the form of an inactivated pathogen) triggers an immune response without the symptoms of ...
DEC 09, 2020
Cancer
Fertility after breast cancer
DEC 09, 2020
Fertility after breast cancer
New data presented at the 2020 San Antonio Breast Cancer Symposium this week dives into the complexities of fertility af ...
DEC 15, 2020
Cancer
New combination therapy may help patients with treatment resistance
DEC 15, 2020
New combination therapy may help patients with treatment resistance
New research from scientists at the UCLA Jonsson Comprehensive Cancer Center showcases a novel combination therapy that ...
JAN 22, 2021
Clinical & Molecular DX
Breast Cancer's Nasty Nine Revealed
JAN 22, 2021
Breast Cancer's Nasty Nine Revealed
Calculating an individual’s risk of developing breast cancer isn’t easy. There’s a complex interplay b ...
JAN 22, 2021
Cancer
Geospacial analysis of HPV vaccination uptake
JAN 22, 2021
Geospacial analysis of HPV vaccination uptake
In an effort to better understand how human papillomavirus (HPV) vaccination varies by geography, researchers from VCU M ...
JAN 27, 2021
Cancer
Does intermittent fasting reduce the risk of postmenopausal breast cancer?
JAN 27, 2021
Does intermittent fasting reduce the risk of postmenopausal breast cancer?
New research in mouse models suggests that intermittent fasting could reduce the risk of metastasis of breast cancer tum ...
Loading Comments...